Physician profile
Marissa Giunta
NPI 1649091653
$764.53
in general payments reported to CMS, 2019-2025
11 companies · $632 in 2025
The $632 reported for 2025 was more than what 75% of Physician Assistant providers received nationally (typical 2025 total: $183).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2024: $132 · 2025: $632.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $765.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $764.53 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Sumitomo Pharma America, INC. | $171.06 | 2024-2025 | Orgovyx, Gemtesa |
| Urogen Pharma, INC. | $161.69 | 2025 | |
| Tolmar, INC. | $92.74 | 2024-2025 | Eligard |
| Progenics Pharmaceuticals, INC. | $78.24 | 2025 | |
| Endo USA, INC. | $67.04 | 2025 | Xiaflex |
| 180 Medical, INC. | $52.68 | 2025 | Gentlecath Glide |
| Dendreon Pharmaceuticals LLC | $40.72 | 2025 | Provenge |
| Olympus America INC. | $35.36 | 2025 | Soltive |
| Boston Scientific Corporation | $28.58 | 2025 | Ams 700 |
| C. R. Bard, INC. & Subsidiaries | $20.36 | 2025 | Bard Urinary Drainage Bag |
| Antares Pharma, INC. | $16.06 | 2025 | Xyosted |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Marissa Giunta listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.